Skip to main content

New Drug Approvals 2013 - Pt. IV - Ospemifene (OSPHENA®)

ATC Code: Not Assigned
Wikipedia: Ospemifene

On February 26, FDA approved Ospemifene (Trade Name: OSPHENAPubChemCID 3036505ChEMBLCHEMBL2105395, ChemSpider2300501) for the treatment of moderate to severe Dyspareunia - symptom of vulvular and vaginal atrophy due to menopause.

Dyspareunia, is pain during or after sexual intercourse. It can affect men, but is significantly more common in women, affecting up to one-fifth of women at some point in their lives. Women with dyspareunia may have pain in the vagina, clitoris or labia. This may be due to medical or psychological causes. There are numerous medical causes of Dyspareunia, like : Vaginismus, Pelvic Inflammatory Disease, Genital or Pelvic Tumors, Urethritis, Urinary Tract Infection, Vaginal Atrophy, Vaginal Dryness, Vulvar Cancer, Childbirth Trauma (postpartum), Skin Conditions (Lichen Sclerosus, Lichen Planus, Eczema, Psoriasis), Female Genital Mutilation, Endometriosis  - many of which can be treatable.

Ospemifene is a novel selective estrogen receptor modulator (SERM) - class of compounds that acts on Estrogen Receptors (ER's). SERM's has a distinguishing characteristic that makes them different from pure receptor agonists and antagonists, which is - that their mode of action is different in various tissues, thereby granting the possibility to selectively inhibit or stimulate estrogen-like action in various tissues (Pub-Med). Ospemifene is an Estrogen agonist/antagonist with tissue selective effects. Its biological actions are mediated through binding to Estrogen Receptors (Short Name: ER, ESR; UniProtQ92731 and P03372ChEMBLCHEMBL2093866). This binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic pathways in others (antagonism).

Mechanism of action of SERM's is of mixed agonism/antagonism which may differ depending on the chemical structure, but, for at least for some SERM's, it appears to be related to -
1. The ratio of co-activator to co-repressor proteins in different cell types.
2. The conformation of the estrogen receptor induced by drug binding, which in turn determines how strongly the drug/receptor complex recruits co-activators (resulting in an agonist response) relative to co-repressors (resulting in antagonism).

The protein sequences of human ER-alpha (ESR1) and ER-beta (ESR2) can be downloaded in fasta format from the link here. (courtesy UniProt)

Compound Name : Z-2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]ethanol
Canonical SMILES : OCCOc1ccc(cc1)\C(=C(\CCCl)/c2ccccc2)\c3ccccc3
Standard InChI : InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-

Ospemifene, an ER agonist/antagonist, has a molecular weight of 378.9. The recommended dosage is 60 mg, available in the form of table for oral administration. After single dosage of Ospemifene under fasted conditions, mean Cmax and AUC (0 to infinity) were 533 ng/mL and 4165, respectively. With a high fat/high diet, mean Cmax and AUC (0 to infinity) were 1198 ng/mL and 7521, respectively. It is highly bound to serum proteins ( >99%) with apparent volume of distribution of 448 L. Ospemifene primarily undergoes metabolism via CYP3A4, CYP2C9 and CYP2C19 and the major metabolite was 4-hydroxyospemifene. Clearance of ospemifene was 9.16 L/hr and terminal half-life was 26 hrs. Following an oral administration of ospemifene, approximately 75% and 7% of the dose was excreted in feces and urine, respectively.

Osphena comes with a boxed warning in the form of Endometrial Cancer and Cardiovascular Disorders. Since Ospemifene is an ER agonist/antagonist with tissue selective effects. In endometrium, due to Ospemifene agonistic effects, there is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy reduces the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. There is a reported increased risk of stroke and deep vein thrombosis in postmenopausal women who received daily oral conjugated estrogens alone therapy over 7.1 years. So, Ospemifene should be prescribed for the shortest duration consistent with treatment goals.

Full prescribing information can be found here.

The license holder is Shionogi Inc., and the product website is


Popular posts from this blog

LSH-based similarity search in MongoDB is faster than postgres cartridge.

TL;DR: In his excellent blog post , Matt Swain described the implementation of compound similarity searches in MongoDB . Unfortunately, Matt's approach had suboptimal ( polynomial ) time complexity with respect to decreasing similarity thresholds, which renders unsuitable for production environments. In this article, we improve on the method by enhancing it with Locality Sensitive Hashing algorithm, which significantly reduces query time and outperforms RDKit PostgreSQL cartridge . myChEMBL 21 - NoSQL edition    Given that NoSQL technologies applied to computational chemistry and cheminformatics are gaining traction and popularity, we decided to include a taster in future myChEMBL releases. Two especially appealing technologies are Neo4j and MongoDB . The former is a graph database and the latter is a BSON document storage. We would like to provide IPython notebook -based tutorials explaining how to use this software to deal with common cheminformatics p

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

Natural Product-likeness in ChEMBL

Recently, we included a Natural Product-likeness score for chemical compounds stored in ChEMBL. We made use of an algorithm published by Peter Ertl, Silvio Roggo and Ansgar Schuffenhauer in 2008 .  Whereas the original version of this algorithm used a commercial data set of Natural Product molecules for training the algorithm (the CRC Dictionary of Natural Products) and an in-house library of synthetic molecules as a negative set, we used Greg Landrum's  RDKit implementation  which is based on  ~50,000 natural products collected from various open databases and ~1 million drug-like molecules from ZINC as a "non-Natural Product background". After including the new score into ChEMBL, we were interested to see whether the results look meaningful. We had a handful of simple questions: How is Natural Product-likeness distributed in ChEMBL and how does this compare to Natural Product-likeness for "real" NPs? Can we observe any difference in Natural Product-likeness for

What is Max Phase in ChEMBL?

ChEMBL contains information on drugs that have been approved for treatment of a specific disease / diagnosis (an indication) within a region of the world (e.g. FDA drugs are approved for use in the United States), and clinical candidate drugs that are being investigated for an indication during the clinical trials process.  The maximum phase of development for the compound across all indications is assigned a category called 'max_phase' (the value in brackets is used in the downloadable ChEMBL database in the 'molecule_dictionary' table): Approved (4): A marketed drug e.g. AMINOPHYLLINE ( CHEMBL1370561 ) is an FDA approved drug for treatment of asthma.  Phase 3 (3): A clinical candidate drug in Phase 3 Clinical Trials e.g. TEGOPRAZAN ( CHEMBL4297583 ) is under clinical investigation for treatment of peptic ulcer at Phase 3, and also liver disease at Phase 1.  Phase 2 (2): A clinical candidate drug in Phase 2 Clinical Trials e.g. NEVANIMIBE HYDROCHLORIDE ( CHEMBL542103 )

ChEMBL 32 is released!

  We are pleased to announce the release of ChEMBL 32! This release of ChEMBL comes with a complete update of drug and clinical candidate information, the addition on a Natural Product likeness score and a harmonization of Journal Name abbreviations according to NLM standards. This version of the database, prepared on 26/01/2023 contains: 2,354,965 compounds (of which 2,327,928 have mol files)             2,995,433 compound records (non-unique compounds) 20,038,828 activities 1,536,903 assays 15,139 targets 86,364 documents   Please see ChEMBL 32 release notes for full details of all changes in this release. Data can be downloaded from the ChEMBL FTP site . Please note that on demand Oracle 19c dumps will not be provided anymore after the ChEMBL 34 release. New Deposited Datasets CHEMBL5058649 - Data for DCP probe BAY 1816032 * CHEMBL5058643 - Data for DCP probe BI-2081 * CHEMBL5058646 - Data for DCP probe CCT369260 * CHEMBL5058644 - Data for DCP probe JNJ-39758979 * CHEMBL5058645 - D